NOV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NOV is not a good immediate buy for a beginner long-term investor with $50,000-$100,000 who is impatient and wants to enter now. The stock is trading near support but the technical trend is weak, analyst views are mixed, and the expected near-term price path is still negative. Long-term upside exists if the offshore and oilfield equipment cycle improves, but right now the better call is to hold rather than buy aggressively.
NOV closed at 18.01, slightly below the previous close of 18.02, showing a flat-to-weak session. MACD histogram is negative at -0.167 and still contracting, which points to ongoing bearish momentum. RSI_6 at 25.877 suggests the stock is short-term oversold, but the broader setup is not yet confirming a reversal. Moving averages are converging, indicating indecision rather than a strong uptrend. Key levels: pivot 18.64, resistance at 19.32 and 19.74, support at 17.96 and 17.54. The stock is sitting close to first support, but the trend does not yet justify an immediate strong buy.
["Citi raised its target to $22 and expects offshore production equipment order growth next year.", "Capital One upgraded the stock to Overweight with a $26 target, signaling improving medium-term optimism.", "BofA kept a Buy rating and raised its target to $23, citing stronger 2027-2028 EBITDA expectations.", "NOV generated nearly $864 million in FY 2025 free cash flow, supporting financial flexibility.", "Several analysts see a potential multi-year upstream spending cycle that could benefit NOV later."]
["Goldman Sachs kept a Sell rating and cut its target to $19, citing caution and incremental costs from Middle East disruption.", "Barclays downgraded NOV to Underweight and said its portfolio is later cycle, with near-term equipment orders likely limited.", "Revenue declined 1.4% in FY 2025 and net margin was only 1.7%, showing weak profitability.", "The stock trend model points to downside over the next week and month.", "Hedge fund and insider activity is neutral, with no meaningful buying signal."]
The latest available financial data is FY 2025. NOV reported about $8.7 billion in revenue, down 1.4% year over year, and net income of about $145 million, which implies thin profitability. The positive highlight was strong free cash flow of nearly $864 million, giving the company flexibility even though top-line growth was soft. The latest quarter season is not provided, so the most recent full-year view suggests stable but sluggish operating performance rather than clear acceleration.
Analyst sentiment is mixed but leaning cautious. Recent target changes have generally moved upward, with Citi, Capital One, BofA, Susquehanna, Evercore, Morgan Stanley, and RBC raising targets, which shows improving medium-term expectations. However, ratings are split: Goldman has a Sell, Barclays downgraded to Underweight, while others remain Neutral, Sector Perform, or Buy-like. Wall Street’s pros argue NOV could benefit from a future offshore and upstream capex cycle and order growth in 2027-2028. The cons are that near-term demand remains weak, the business is later-cycle, and cost pressures and geopolitical disruption are still weighing on results. No politicians or influential figures were reported buying or selling NOV, and there is no recent congress trading data.
